Ignite Creation Date:
2025-12-25 @ 1:08 AM
Ignite Modification Date:
2026-02-28 @ 8:19 AM
Study NCT ID:
NCT02932293
Status:
WITHDRAWN
Last Update Posted:
2017-05-12
First Post:
2016-10-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Triple Combination DAAs for Treating HCV GT1b Subjects
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 0}}, 'statusModule': {'whyStopped': 'The collaborating pharmaceutical company will not wish to continue with the trial due to the internal issues in the company.', 'overallStatus': 'WITHDRAWN', 'startDateStruct': {'date': '2016-12', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-10', 'completionDateStruct': {'date': '2017-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-05-11', 'studyFirstSubmitDate': '2016-10-05', 'studyFirstSubmitQcDate': '2016-10-12', 'lastUpdatePostDateStruct': {'date': '2017-05-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-10-13', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of participants with plasma HCV viral load below the lower limit of quantification for 12 weeks after treatment completion (SVR12)', 'timeFrame': 'Post treatment Week 12', 'description': 'SVR12 is defined as HCV RNA \\< lower limit of quantification (LLOQ) 12 weeks after last dose of study drug.'}], 'secondaryOutcomes': [{'measure': 'Frequency and severity of adverse events', 'timeFrame': 'Baseline up to Week 24'}, {'measure': 'Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment', 'timeFrame': 'Baseline up to Week 24'}, {'measure': 'Kinetics of circulating HCV RNA during treatment and after treatment discontinuation', 'timeFrame': 'Baseline up to Week 24'}, {'measure': 'Proportion of participants with on-treatment virologic breakthrough and relapse', 'timeFrame': 'Baseline up to Week 24', 'description': 'Viral breakthrough is defined as having achieved undetectable HCV RNA levels (HCV RNA \\< LLOQ) during treatment, but did not achieve a sustained virologic response (SVR). Viral relapse is defined as having achieved undetectable HCV RNA levels (HCV RNA \\< LLOQ) within 4 weeks of end of treatment, but did not achieve an SVR up to 24 weeks.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ['Chronic Hepatitis C Infection']}, 'descriptionModule': {'briefSummary': "There is only one kind of treatment (simeprevir 150 mg + sofosbuvir 400 mg+daclatasvir 60 mg) in this study but the treatment duration may be different depending on patients' response to the antiviral therapy and whether patients have liver cirrhosis. If patients have no cirrhosis and the HCV viral load on day 2 is \\<500 IU/ml, patients will receive sofosbuvir, daclatasvir and simeprevir for 3 weeks, otherwise the treatment duration is 4 weeks. If patients have cirrhosis and the HCV viral load on day 2 is \\<500 IU/ml, patients will receive sofosbuvir, daclatasvir and simeprevir for 6 weeks, otherwise the treatment duration will be 8 weeks."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. HCV RNA positive \\>2000 IU/ml or NAT POC positive\n2. Genotype 1b\n3. CP score ≤6\n\nExclusion Criteria:\n\n1. Pregnant or nursing female or male with pregnant female partner\n2. Hematologic or biochemical parameters at Screening outside the protocol- specified requirements\n3. Active or recent history (≤ 1 year) of drug or alcohol abuse\n4. Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers)\n5. History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate."}, 'identificationModule': {'nctId': 'NCT02932293', 'briefTitle': 'Triple Combination DAAs for Treating HCV GT1b Subjects', 'organization': {'class': 'OTHER', 'fullName': 'Humanity and Health Research Centre'}, 'officialTitle': 'Triple Combination DAAs for Ultra Short Duration Therapy for HCV Genotype 1b in Chinese (SODAPI II Study)', 'orgStudyIdInfo': {'id': 'H&H_SODAPI II'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'SOF+DCV+SMV 3-4 wks', 'description': 'Patients without cirrhosis will receive sofosbuvir, daclatasvir and simeprevir for (a) 3 weeks if HCV viral load on day 2 is \\<500 IU/ml or (b) 4 weeks if HCV viral load on day 2 is \\>500 IU/ml.', 'interventionNames': ['Drug: SOF+DCV+SMV']}, {'type': 'EXPERIMENTAL', 'label': 'SOF+DCV+SMV 6-8 wks', 'description': 'Patients with cirrhosis and CP-A will receive sofosbuvir, daclatasvir and simeprevir (a) 6 weeks if HCV VL on day 2 is \\<500 IU/ml or (b) 8 weeks if HCV VL on day 2 is \\>500 IU/ml.', 'interventionNames': ['Drug: SOF+DCV+SMV']}], 'interventions': [{'name': 'SOF+DCV+SMV', 'type': 'DRUG', 'description': 'Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.', 'armGroupLabels': ['SOF+DCV+SMV 3-4 wks', 'SOF+DCV+SMV 6-8 wks']}]}, 'contactsLocationsModule': {'locations': [{'zip': '00852', 'city': 'Hong Kong', 'country': 'Hong Kong', 'facility': 'Humanity and Health Medical Centre', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}], 'overallOfficials': [{'name': 'George LAU, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Humanity & Health Medical Centre'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Humanity and Health Research Centre', 'class': 'OTHER'}, 'collaborators': [{'name': 'University of Maryland', 'class': 'OTHER'}, {'name': 'Emory University', 'class': 'OTHER'}, {'name': 'Beijing 302 Hospital', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}